AI Article Synopsis
- The HeartMate 3, a left ventricular assist device, has shown great success in improving patient outcomes, but complications like pump thrombosis remain a concern.
- A case study discusses a 68-year-old man who, after 19 months with the device, experienced heart failure and cardiogenic shock, with no clear diagnosis from clinical assessments.
- Surgical exploration ultimately uncovered clots in the device, highlighting a vulnerability that the authors suggest could be addressed through minor enhancements from the manufacturer.
Article Abstract
Even if the HeartMate 3 left ventricular assist device is associated with excellent outcomes, complications, such as pump thrombosis continue to affect patients on hemodynamic support. We report the history of a 68-year-old man who underwent implantation of an HeartMate 3 as a bridge to transplantation. Nineteen months later, he developed signs of heart failure leading to cardiogenic shock. Neither clinical examination nor parameters from the device allowed a clear-cut diagnosis. Only surgical exploration revealed the presence of clots between the polyethylene terephthalate (Dacron®) and polytetrafluoroethylene tubes. This constitutes a weakness of this device for which we propose to the manufacturer for minimal modifications to overcome the problem.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0267659119890218 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expert-Based Narrative Review on Compression UltraSonography (CUS) for Diagnosis and Follow-Up of Deep Venous Thrombosis (DVT).
Diagnostics (Basel)
January 2025
Research Center on Thromboembolic Diseases and Antithrombotic Treatment, Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy.
Deep venous thrombosis (DVT) is a pathological condition that develops when a thrombus forms within the deep venous system. Typically, it involves the lower limbs and, less frequently, the upper extremities or other unusual districts such as cerebral or splanchnic veins. While leg DVT itself is rarely fatal and occasionally can lead to limb-threatening implications, its most fearsome complication, namely pulmonary embolism, is potentially fatal and significantly contributes to increased healthcare costs and impaired quality of life in affected patients and caregivers.
View Article and Find Full Text PDFUpper Arm Deep Vein Thrombosis in a Patient with Active Lupus.
Eur J Case Rep Intern Med
December 2024
Radiology Department, Seychelles Hospital, Healthcare Agency, Victoria, Seychelles.
Unlabelled: Upper extremity deep vein thrombosis (UEDVT) is relatively rare, and much less as an initial presentation of systemic lupus erythematosus (SLE). Primary UEDVT should be considered in individuals with unilateral arm swelling where the brachial, axillary, and subclavian veins are frequently involved. SLE is a chronic autoimmune disease that predominantly affects women of childbearing age and of African descent.
View Article and Find Full Text PDFAtrial Septal Defect Occluder-Induced Left Atrial Injury: A Paradoxical Source of Embolic Strokes.
Ann Thorac Surg Short Rep
September 2024
Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.
Transcatheter atrial septal defect closure is a prevalent minimally invasive treatment option but still has cerebrovascular accident (CVA) risk. An unusual thromboembolic CVA cause is device-related mechanical atrial injury. We describe the case of a patient with prior transcatheter atrial septal defect closure who had ongoing CVA despite anticoagulation.
View Article and Find Full Text PDFRisk Factors for Venous Thromboembolism in Acute Promyelocytic Leukemia.
Cancers (Basel)
December 2024
Clinic of Hematology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
Background: Acute promyelocytic leukemia (APL) is frequently associated with disseminated intravascular coagulation (DIC), leading to potentially life-threatening bleeding. Compared to bleeding, thromboses are a less commonly encountered problem.
Objective: The objective of our study was to identify the incidence and predictive value of demographic data, clinical-laboratory parameters, and thrombosis risk assessment models (RAMs) for venous thromboembolism (VTE) in patients with APL.
Effect of Antithrombin Leakage From Hemodialysis Therapy on Antithrombin Hemodynamics.
Cureus
December 2024
Clinical Laboratory Science, Graduate School of Medical Science, Kanazawa University, Kanazawa, JPN.
Introduction Hemodialysis (HD) therapy is a crucial treatment for patients with renal failure but can impact the hemodynamics of antithrombin (AT), a protein essential for regulating hemostasis and preventing thrombosis. Reduced AT activity can lead to thrombus formation at unusual sites and increase the risk of recurrent venous thromboembolism. The loss of AT during HD or hemodiafiltration (HDF) through leakage or adsorption onto dialysis membranes has not been fully investigated, and its effects on AT hemodynamics remain unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!